AR006311A1 - Un inhibidor de la serina proteasa - Google Patents
Un inhibidor de la serina proteasaInfo
- Publication number
- AR006311A1 AR006311A1 ARP970100834A ARP970100834A AR006311A1 AR 006311 A1 AR006311 A1 AR 006311A1 AR P970100834 A ARP970100834 A AR P970100834A AR P970100834 A ARP970100834 A AR P970100834A AR 006311 A1 AR006311 A1 AR 006311A1
- Authority
- AR
- Argentina
- Prior art keywords
- chr2
- amino acid
- r2ooc
- alkyl
- optionally substituted
- Prior art date
Links
- 229940122055 Serine protease inhibitor Drugs 0.000 title 1
- 101710102218 Serine protease inhibitor Proteins 0.000 title 1
- 239000003001 serine protease inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- -1 alpha-hydroxyacetyl Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 230000002209 hydrophobic effect Effects 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 2
- 230000007935 neutral effect Effects 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
- 150000008574 D-amino acids Chemical class 0.000 abstract 1
- 150000008575 L-amino acids Chemical group 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
- C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Un compuesto que tiene la fórmula (I), que comprende: A es H, D, L alfa- hidroxiacetilo opcionalmente substituido, R1, R1-O-C(O)-, R1-C(O)-,R1-SO2-,R2OOC-(CHR2)m-SO2-, R2OOC-(CHR2)m-, H2NCO-(CHR2)m, o un grupo N-protector, en donde R1 essele ccionado entre (1-12C)alquilo, (2-12C)alquenilo,(2-12C)-alquinilo y (3-8C)ciacloalquilo, grupos que pueden ser opcionalmente substituidos con (3-8C)cicloalquilo, (1-6C)-alcoxi, oxo, OH, COOH, CF3 ohalógeno, y de (6-14C)arilo,(7-15C)aralqu ilo y (8-16)aralquenilo, cuyos grupos arilo pueden ser opcionalmente substituidos con (1-6C)alquilo,(3-8C)-cicloalquilo, (1-6C)alcoxi, OH, COOH, CF3 o halógeno; cada grupo R2 es independientemente H o tiene el mismosignificado que R1; m es 1, 2 o 3; Bes un enlace, un aminoácido de la fórmula -NH-CH[(CH2)pC(O)OH]-C(O)- o un derivado éster del mismo y siendo p igual a 0, 1, 2 o 3, -N((1-12C)alquilo-CH2-CO-, -N((2-12C)alquinilo)-CH2-CO-,-N(bencilo)-CH2-CO-, D-1-Tiq, D-3-T iq, D-Atc, Aic, D-1-Piq, D-3-Piq o un -L o D-aminoácido que tiene unacadena lateral hidrófoba, básica o neutra, aminoácido que puede estar opcionalmente substituido con N-(1-6C)alquilo; o A y Bjuntos son el residuoR3R4N-CHR5-C(O)-, en dond e R3 y R4 independientemente son R1, R1-O-C(O)-, R1-SO2-, R2OOC-(CHR2)m-SO2-, R2OOC-(CHR2)m-, H2NCO-(CHR2)m-, o un grupoN-protector, o uno de R3 y R4 está conectado con R5 para formar un anillo de5 o 6 miembros junto con N-C al cual están uni dos, anillo que puede serfusionado con un anillo de 6 miembros alifático o aromático; y R5 es una cadena lateral hidrófoba, básica o neutra; X es un L-aminoácido con una cadenalateral hidrófoba,serina, treonina, un aminoácido cíclico que cont iene opcionalmente un heteroátomo adicional seleccionado entre N, O o S, y
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96200545 | 1996-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR006311A1 true AR006311A1 (es) | 1999-08-25 |
Family
ID=8223738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970100834A AR006311A1 (es) | 1996-03-01 | 1997-03-03 | Un inhibidor de la serina proteasa |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6218365B1 (es) |
| EP (1) | EP1012164B1 (es) |
| JP (1) | JP2000506838A (es) |
| KR (1) | KR19990087416A (es) |
| CN (1) | CN1212705A (es) |
| AR (1) | AR006311A1 (es) |
| AT (1) | ATE277074T1 (es) |
| AU (1) | AU715765B2 (es) |
| BR (1) | BR9707812A (es) |
| CA (1) | CA2246722A1 (es) |
| CZ (1) | CZ277998A3 (es) |
| DE (1) | DE69730871D1 (es) |
| HU (1) | HUP9901503A3 (es) |
| ID (2) | ID16105A (es) |
| IL (1) | IL120311A (es) |
| NO (1) | NO983992L (es) |
| NZ (1) | NZ331486A (es) |
| PL (1) | PL328665A1 (es) |
| TR (1) | TR199801705T2 (es) |
| TW (1) | TW523513B (es) |
| WO (1) | WO1997031939A1 (es) |
| ZA (1) | ZA971733B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2289625A1 (en) | 1997-05-15 | 1998-11-19 | Charles Van Jackson | Antithrombotic compound |
| US6344450B1 (en) * | 1999-02-09 | 2002-02-05 | Bristol-Myers Squibb Company | Lactam compounds and their use as inhibitors of serine proteases and method |
| JP2002542165A (ja) | 1999-04-09 | 2002-12-10 | ビーエーエスエフ アクチェンゲゼルシャフト | トロンビンインヒビターのプロドラッグ |
| WO2002006280A2 (en) * | 2000-07-13 | 2002-01-24 | Millennium Pharamaceuticals, Inc. | INHIBITORS OF FACTOR Xa |
| WO2002060894A2 (en) | 2001-01-30 | 2002-08-08 | Bristol-Myers Squibb Company | Sulfonamide lactam inhibitors of factor xa |
| US6716869B2 (en) * | 2001-12-17 | 2004-04-06 | Pharmacia Corporation | Protease inhibitors of the coagulation cascade isolated from Dysidea sponges |
| AU2003248584A1 (en) * | 2002-03-01 | 2003-09-16 | Warner-Lambert Company Llc | Method of treating osteoarthritis |
| US7439226B2 (en) * | 2003-09-30 | 2008-10-21 | The United States Of America As Represented By The Department Of Health And Human Services | Serine protease inhibitors |
| JP2008521853A (ja) * | 2004-12-02 | 2008-06-26 | プロビオドルグ エージー | 神経疾患治療用の新規化合物 |
| RU2419626C2 (ru) | 2006-05-23 | 2011-05-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
| RU2419625C2 (ru) * | 2006-05-23 | 2011-05-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
| EA016327B1 (ru) | 2007-02-09 | 2012-04-30 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
| JP2010518097A (ja) * | 2007-02-09 | 2010-05-27 | アイアールエム・リミテッド・ライアビリティ・カンパニー | チャネル活性化プロテアーゼ阻害剤としての化合物および組成物 |
| WO2017222914A1 (en) | 2016-06-21 | 2017-12-28 | Inception 4, Inc. | Carbocyclic prolinamide derivatives |
| EP3472149B1 (en) | 2016-06-21 | 2023-08-30 | Orion Ophthalmology LLC | Heterocyclic prolinamide derivatives |
| DE102020103516B4 (de) | 2020-02-11 | 2023-12-07 | Universität Zu Lübeck | Antivirale Wirkstoffe mit breiter Aktivität |
| US11124497B1 (en) | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| US11174231B1 (en) | 2020-06-09 | 2021-11-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| KR20230040386A (ko) * | 2020-06-09 | 2023-03-22 | 파르데스 바이오사이언시스, 인크. | 시스테인 프로테아제의 억제제 및 이의 사용 방법 |
| AU2021289665A1 (en) | 2020-06-10 | 2022-12-15 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| IL309732A (en) | 2021-07-09 | 2024-02-01 | Aligos Therapeutics Inc | Antiviral compounds |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2159834A1 (en) * | 1993-04-30 | 1994-11-10 | Daniel F. Veber | Thrombin inhibitors |
| US5672582A (en) * | 1993-04-30 | 1997-09-30 | Merck & Co., Inc. | Thrombin inhibitors |
| SE9301916D0 (sv) * | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| IL112795A (en) * | 1994-03-04 | 2001-01-28 | Astrazeneca Ab | Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them |
| JPH10503176A (ja) * | 1994-06-17 | 1998-03-24 | コーバス インターナショナル， インコーポレイテッド | 酵素インヒビターとしての３−アミノ−２−オキソ−１−ピペリジン酢酸誘導体 |
| JPH0820597A (ja) * | 1994-07-07 | 1996-01-23 | Meiji Seika Kaisha Ltd | トロンビン阻害作用を有する複素環カルボニル化合物 |
| WO1996019483A1 (en) * | 1994-12-22 | 1996-06-27 | Biochem Pharma Inc. | Low molecular weight bicyclic thrombin inhibitors |
| PL328307A1 (en) * | 1996-02-13 | 1999-01-18 | Akzo Nobel Nv | Serinic protease inhibitors |
-
1997
- 1997-02-25 IL IL12031197A patent/IL120311A/en not_active IP Right Cessation
- 1997-02-25 TW TW086102260A patent/TW523513B/zh active
- 1997-02-26 AT AT97903384T patent/ATE277074T1/de not_active IP Right Cessation
- 1997-02-26 DE DE69730871T patent/DE69730871D1/de not_active Expired - Lifetime
- 1997-02-26 BR BR9707812A patent/BR9707812A/pt unknown
- 1997-02-26 JP JP9530601A patent/JP2000506838A/ja not_active Withdrawn
- 1997-02-26 CN CN97192688A patent/CN1212705A/zh active Pending
- 1997-02-26 KR KR1019980706834A patent/KR19990087416A/ko not_active Ceased
- 1997-02-26 HU HU9901503A patent/HUP9901503A3/hu unknown
- 1997-02-26 AU AU17956/97A patent/AU715765B2/en not_active Ceased
- 1997-02-26 EP EP97903384A patent/EP1012164B1/en not_active Expired - Lifetime
- 1997-02-26 PL PL97328665A patent/PL328665A1/xx unknown
- 1997-02-26 CA CA002246722A patent/CA2246722A1/en not_active Abandoned
- 1997-02-26 CZ CZ982779A patent/CZ277998A3/cs unknown
- 1997-02-26 TR TR1998/01705T patent/TR199801705T2/xx unknown
- 1997-02-26 NZ NZ331486A patent/NZ331486A/xx unknown
- 1997-02-26 WO PCT/EP1997/000939 patent/WO1997031939A1/en not_active Ceased
- 1997-02-26 US US09/142,068 patent/US6218365B1/en not_active Expired - Fee Related
- 1997-02-27 ZA ZA9701733A patent/ZA971733B/xx unknown
- 1997-03-03 ID IDP970634A patent/ID16105A/id unknown
- 1997-03-03 ID IDP970633A patent/ID16104A/id unknown
- 1997-03-03 AR ARP970100834A patent/AR006311A1/es unknown
-
1998
- 1998-08-31 NO NO983992A patent/NO983992L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9901503A3 (en) | 2001-10-29 |
| TR199801705T2 (xx) | 1998-12-21 |
| KR19990087416A (ko) | 1999-12-27 |
| IL120311A0 (en) | 1997-06-10 |
| EP1012164A1 (en) | 2000-06-28 |
| WO1997031939A1 (en) | 1997-09-04 |
| EP1012164B1 (en) | 2004-09-22 |
| CZ277998A3 (cs) | 1999-02-17 |
| ID16104A (id) | 1997-09-04 |
| HUP9901503A2 (hu) | 1999-08-30 |
| ZA971733B (en) | 1997-09-10 |
| DE69730871D1 (de) | 2004-10-28 |
| ID16105A (id) | 1997-09-04 |
| NZ331486A (en) | 1999-07-29 |
| NO983992D0 (no) | 1998-08-31 |
| AU715765B2 (en) | 2000-02-10 |
| TW523513B (en) | 2003-03-11 |
| AU1795697A (en) | 1997-09-16 |
| ATE277074T1 (de) | 2004-10-15 |
| JP2000506838A (ja) | 2000-06-06 |
| CN1212705A (zh) | 1999-03-31 |
| CA2246722A1 (en) | 1997-09-04 |
| BR9707812A (pt) | 1999-07-27 |
| IL120311A (en) | 2001-10-31 |
| NO983992L (no) | 1998-10-30 |
| PL328665A1 (en) | 1999-02-15 |
| US6218365B1 (en) | 2001-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR006311A1 (es) | Un inhibidor de la serina proteasa | |
| AR006310A1 (es) | Un inhibidor de la serina proteasa, una composicion farmaceutica que comprende dicho inhibidor y usos de dicho inhibidor | |
| AR012631A1 (es) | Inhibidores de la proteasa de serina | |
| ES2001056A6 (es) | Un procedimiento para la preparacion de polipeptidos y sus derivados que contienen oxa- y azahomocicloestatina. | |
| FI924311A0 (fi) | Nya 2-substituerade indan-2 -merkaptoacetylamidderivat anvaendbara som inhibitorer av enkefalinas och ace. | |
| NO914092D0 (no) | Fremgangsmaate for fremstilling av mercaptoacetylamidderivater | |
| AR240940A2 (es) | Procedimiento para la preparacion de derivados de amino-substituido 1-carboxi-oxopirazolo- y -oxopiradazo/1, 2-a/piridazina y -/1,2/ diazepina e intermediarios para uso exclusivo en dicho procedimiento" | |
| SE7713721L (sv) | Substituerade acylderivat av aminosyror | |
| DE69329304D1 (de) | Enzymatische Verfahren zur Resolution von Enantiomeren-Mischungen nützlich wie Zwischenprodukte zur Herstellung von Taxanen | |
| FI943728A0 (fi) | Enkefalinaasin ja ACE:n inhibiittoreina käyttökelpoisia uusia aminoasetyylimerkaptojohdannaisia | |
| ES2032596T3 (es) | Composiciones inhibidoras de corrosion. | |
| AU5736494A (en) | Cyclic sulfone containing retroviral protease inhibitors | |
| MX172150B (es) | Composicion de detergente liquida que contiene enzima y sistema de estabilizacion | |
| ES2195382T3 (es) | Compuestos indolcarboxilicos y su uso como compuestos farmaceuticos. | |
| ECSP941068A (es) | Derivados de la cefalosporina | |
| NO168172C (no) | Forbindelser for detektering av naervaeret av hydrolytiske bestanddeler i en proeve | |
| DE3462039D1 (en) | Peptide derivatives, their preparation and use as elastase inhibitors | |
| ES2055020T3 (es) | Derivados de acidos azo-carboxilicos aromaticos biocidas. | |
| ATE19884T1 (de) | Verfahren zur herstellung von phosphonomethylierten aminosaeuren. | |
| ES2091280T3 (es) | Composicion detergente liquida que contiene lipasa y proteasa. | |
| ES2060123T3 (es) | Aminoacidos protegidos y procedimientos para su fabricacion. | |
| ES2058383T3 (es) | Derivados de acidos carboxilicos azaciclicos, su preparacion y uso. | |
| AR016403A1 (es) | Metodo para intensificar la actividad de una enzima | |
| AR005807A1 (es) | Un inhibidor de la serina proteasa, su uso y una composicion farmaceutica que lo comprende | |
| ES2081858T3 (es) | Compuestos de beta-fenoxinitrilo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |